Zenalpha® (medetomidine and vatinoxan hydrochlorides injection)
For intramuscular (IM) injection in dogs only. Zenalpha® is indicated for use as a sedative and analgesic in dogs to facilitate clinical examinations, clinical procedures and minor surgical procedures. Available in 10 mL multi-dose glass vials, Zenalpha® has a short time to onset of sedation of 5-15 minutes and a short duration of sedation of approximately 45 minutes in most dogs.
| Active(s)/Ingredient(s): | Medetomidine hydrochloride, Vatinoxan hydrochloride |
| Pack size(s): | 10ml |
| Documents: | Package insert get_app SDS get_app |
Important safety information
As with all drugs, side effects may occur. For use in dogs only. Not intended for use in cats. Not for use in humans. Avoid skin, eye or mucosal contact. In case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician. DO NOT DRIVE as sedation, loss of consciousness, and changes in blood pressure may occur. People with cardiovascular disease and pregnant women should exercise special caution to avoid exposure. Uterine contractions and decreased fetal blood pressure may occur after accidental systemic exposure. As with all alpha-2 adrenoceptor agonists, onset of sedation may be delayed or may be inadequate in some dogs. Do not use Zenalpha® in dogs with cardiac disease, respiratory disorders, shock, severe debilitation, that have hypoglycemia or are at risk of developing hypoglycemia, or are stressed due to extreme heat, cold or fatigue. Zenalpha® should not be administered in the presence of pre-existing hypotension, hypoxia or bradycardia. Due to the pronounced cardiovascular effects of alpha-2 adrenoceptor agonists, only clinically healthy dogs (American Society of Anesthesiologists [ASA] classes I and II) should be administered Zenalpha®. Dogs should be monitored frequently during sedation for changes in heart rate, blood pressure, respiratory rate and body temperature. Tachycardia may occur in some dogs after recovery from sedation. The following adverse reactions have been reported: diarrhea, muscle tremors and colitis. Refer to the prescribing information for complete details or visit www.dechra-us.com.